Finerenone in the management of Diabetic Kidney Disease: A consensus statement by the Association of British Clinical Diabetologists and UK Kidney Association

This consensus statement by the Association of British Clinical Diabetologists and UK Kidney Association provides context and recommendations regarding the use Finerenone in the management of Diabetic Kidney Disease.

Finerenone in the management of Diabetic Kidney Disease: A consensus statement by the Association of British Clinical Diabetolog

Discipline:

Diabetes

Endocrinology

Clinical taxonomy:

Chronic kidney disease

Type 2 diabetes mellitus

Resource taxonomy:

Position Paper

Privacy Policy | Website Terms and Conditions

Address for correspondence: ABCD (Diabetes Care) Ltd, 483 Green Lanes, London, N13 4BS

Telephone: 01675 477602 Email: info@abcd.care

ABCD (Diabetes Care) is a company limited by shares in England and Wales under company number 7270377, whose registered address is Sterling House, 1 Sheepscar Court, Meanwood Road, Leeds LS7 2BB. Diabetes Care Trust (ABCD) is a registered charity number 1139057, a company limited by guarantee in England and Wales under company number 74248361,whose registered address is Sterling House, 1 Sheepscar Court, Meanwood Road, Leeds LS7 2BB. ABCD (Diabetes Care) Ltd is a wholly owned subsidiary of the Diabetes Care Trust (ABCD) Ltd

ABCD Corporate Pharma Sponsors; Gold: Astra Zeneca, Lilly, Sanofi. Silver: A.Menarini Farmaceutica Internazionale SRL,

ABCD Corporate Pump & Device Supporters, Gold: Abbott Laboratories Ltd, Dexcom, GlucoRx, Insulet International Ltd, Ypsomed Ltd; Silver: Air Liquide Healthcare Ltd, Medtrum Ltd, Menarini Diagnostics; Bronze: Roche Diabetes Care.

Read the ABCD statement on pharmaceutical industry funding

Search form

You are here

Finerenone in the management of Diabetic Kidney Disease: A consensus statement by the Association of British Clinical Diabetologists and UK Kidney Association

ABCD Webinar Series